We are a nuclear medicine technology company committed to providing the United States with stable, domestic and environmentally friendly radioisotope supply solutions to meet the needs of patients and advance clinical research. Our innovative technologies have the ability to fundamentally transform the ways that medical radioisotopes are produced and distributed around the world.
BELOIT, Wis. – April 23, 2019 – NorthStar Medical Technologies, LLC, (“NorthStar” or the “Company”) a global innovator in the production and distribution of radioisotopes used for medical imaging and therapy, today announced the closing of a $100 million secured financing with funds managed by Oberland Capital Management LLC (“Oberland Capital”).
– Accelerator technology key component of NorthStar’s multi-pronged Mo-99 production strategy – BELOIT, Wis.
– Positive RadioGenix System market momentum continues – – Increasing weekly domestic production of non-uranium based Mo-99 – Highlights include: Strategically-planned RadioGenix System roll out on track; initial units in use Numerous RadioGenix System commercial sites in regulatory licensure review process; many additional sites anticipated in 2019 Every week, an increasing number of technetium-99m (Tc-99m) patient doses are dispensed using RadioGenix Systems and non-uranium molybdenum-99 (Mo-99) NorthStar recognized by U.S.
Questions about company, products, supply solutions, careers or anything else?